Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
This real-world study showed that in patients with BRAF V600E-mutated mCRC treated with encorafenib/cetuximab +/- binimetinib, efficacy and safety data confirm those reported in the BEACON registration trial. The main poor prognostic factors for this treatment are synchronous metastases and ECOG-PS >1.
Authors
- Antoine Drouillard
- Solène Doat
- Julien Taı̈eb (ORCID: https://orcid.org/0000-0002-9955-4753)
- Sebastian Stintzing (ORCID: https://orcid.org/0000-0002-3297-5801)
- Andrea Sartore‐Bianchi (ORCID: https://orcid.org/0000-0003-0780-0409)
- Édouard Auclin (ORCID: https://orcid.org/0000-0001-7039-4840)
- Anthony Turpin (ORCID: https://orcid.org/0000-0002-2282-0101)
- David Tougeron (ORCID: https://orcid.org/0000-0002-8065-9635)
- M. Jary
- Pascal Artru (ORCID: https://orcid.org/0000-0002-9777-0866)
- Elisabeth Sophie Bergen (ORCID: https://orcid.org/0000-0002-0374-1408)
- Vanessa Wookey
- Géraldine Perkins (ORCID: https://orcid.org/0000-0002-4960-2534)
- Isabelle Trouilloud
- Julie Lavolé (ORCID: https://orcid.org/0000-0002-2450-6618)
- Hans Prenen (ORCID: https://orcid.org/0000-0001-8802-7352)
- Chloé Melchior (ORCID: https://orcid.org/0000-0002-8146-1540)
- T. Mazard
- Audrey Perret
- Simon Pernot (ORCID: https://orcid.org/0000-0003-4580-585X)
- Javier Ros (ORCID: https://orcid.org/0000-0002-8137-5415)
- C. Gallois
- Debora Basile (ORCID: https://orcid.org/0000-0003-1457-2272)
- Olivier Dubreuil (ORCID: https://orcid.org/0000-0003-0525-0423)
- Yann Touchefeu (ORCID: https://orcid.org/0000-0001-8421-3182)
- Steven Cuissy
- Jules Higué
- Andrea Alberti (ORCID: https://orcid.org/0000-0002-1619-1986)
- Lorenzo Pilla
Institutions
- Centre National de la Recherche Scientifique (FR)
- Mayo Clinic (US)
- Inserm (FR)
- University of Milan (IT)
- Université Paris Cité (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Université de Poitiers (FR)
- Sorbonne Université (FR)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Assistance Publique – Hôpitaux de Paris (FR)
- Antwerp University Hospital (BE)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Saint-Antoine (FR)
- University of Clermont Auvergne (FR)
- Nuovo Ospedale San Giovanni di Dio (IT)
- Centre Léon Bérard (FR)
- Hôpital Européen (FR)
- Groupe Hospitalier Diaconesses Croix Saint-Simon (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpital Pontchaillou (FR)
- Hôpital Privé Jean Mermo (FR)
- Vall d'Hebron Hospital Universitari (ES)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Hôpital d'Instruction des Armées Bégin (FR)
- Institut Bergonié (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Maison des Sciences sociales et des Humanités de Dijon (FR)
- Onco Lille (FR)
- Université de Rouen Normandie (FR)
- Medical University of Vienna (AT)
- Charité - Universitätsmedizin Berlin (DE)
- University of Brescia (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103696
- Citations
- 20
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.65
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Merck KGaA
- Les Laboratories Pierre Fabre
- Incyte
- Astellas Pharma
- Servier
- Genentech